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Introduction:  
Chronic renal failure (CRF) represents one of the most expensive and rapidly growing demands on the 
health-care system of developed and developing countries. Its incidence appears to be increasing, 
particularly in some developing countries (1). Iron deficiency is considered the most common cause of 
inadequate response to recombinant human erythropoietin (r-HuEPO). Therefore, body iron stores should 
be assessed regularly and accurately. Body stores of iron are usually assessed by transferrin saturation 
(TSAT) (normal 20%-30%) and serum ferritin levels (normal >150 ng/ml). TSAT and serum ferritin are 
extensively used in clinical practice in monitoring iron status in patients with chronic kidney failure (CKD) 
on r-HuEPO treatment (2, 3). In view of the relatively poor status of the health-care system in the developing 
world, there is an obvious need for reduction of the mortality rate through the reduction of the cost of 
dialysis, treatment and renal transplantation.In spite of the considerable efforts dedicated to the CRF 
patients, and the remarkable improvement in the quality of renal replacement therapy, such as increased 
dose of dialysis and the use of erythropoietin and biocompatible membranes, the annual mortality among 
dialysis patients remains high(4).Reports on the aetiology as well as monitoring the iron status in CRF 
patients in Central Sudan is scanty and based on retrospective data. In this study, the causes of ESRD in 
Sudanese patients and their iron status are described  
  
Methods:  
This is a cross sectional hospital based study of 68 Sudanese patients with CRF.  
They receive regular haemodialysis at Gezira Hospital for Kidney Diseases and Transplantation in Gezira 
State, Central Sudan during the period of January 2011 to December 2011.The patients were selected based 
Abstract:  
Background:  This cross sectional study was conducted to determine the possible causes of chronic renal 
failure (CRF) and to monitor the iron status in order to reduce the mortality and morbidity in dialysis 
patients.  
Resluts:  Sixty eight CRF patients (36 men and 32 women) on regular haemodialysis were included in 
this study. Their mean age was 45.4 ± 17.8 years. Diabetes nephropathy (29%) was the commonest cause 
of CRF, followed by hypertension (21%) 
Glomerulonephritis (15%), Severe malaria (13%) and the least common one was polycystic kidney (3%). 
The mean serum iron was 57.7 ± 27.9 ng/ml, mean serum ferritin was 221.0 ± 170.1 ng/ml, and transferrin 
saturation (TSAT) was 22.8 ± 24.3%. Using TSAT, 15 (22.1%) patients had adequate (or normal) iron 
status (25.9 ± 4.4; 284.6 ± 111.0), 53 (77.9%) patients had iron deficiency (13.8 ± 2.6; 88.8 ± 37.7) and 
none had iron overload.   
Conclusion:  Our study suggests that, diabetes and hypertension are the conditions requiring strategies 
for prevention and treatment, and iron status of most cases is poor.    
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on a questionnaire and clinical examination. The questionnaire was developed to include the relevant 
information such as: age, sex, presenting symptoms, past history, duration of dialysis…. etc. Further 
information including complication and treatment were obtained from patient’s files. After explaining the 
purpose of this study, a written consent was obtained from each patient. Blood samples (5 ml) were 
collected from each patient transferred into vials coated with anti-coagulant (EDTA) and analyzed for 
serum iron, total iron binding capacity (TIBC) and ferritin using fully automated chemical analyzer. 
Transferrin saturation (TSAT) is calculated as the ratio of serum iron and TIBC. The values reported are 
the means and standard deviations. The results obtained were compared with the reference value cited for 
each parameter.  
  
Results:  
Of the 68 CRF patients, 36 (53%) were men and 32 (47%) were women. The mean age was 45.4 ± 17.8 
years and ranged from 10 to 78 years. Disease duration was presented in (Figure 1). Diabetes nephropathy 
was the commonest cause of CRF diagnosed in 18 (29%) patients followed by hypertension in 13 (21%), 
glomerulonephritis (15%), severe malaria (13%) and the least common one was polycystic kidney (3%), 
(Table 1). As shown in Table 2, hypertension was the most common complication among the study subjects 
which was found in 34 (74%) patients, hypertension and heart failure in 6 (13%) cases. The laboratory 
parameters are shown in Table 3. The mean serum iron was 57.7 ± 27.9 ng/ml, mean serum ferritin was 
221.0 ± 170.1 ng/ml, and transferrin saturation (TSAT) was 22.8 ± 24.3%.   
Using TSAT and Serum ferritin, 15 (22.1%) patients had adequate (or normal) iron status (25.9 ± 4.4; 284.6 
± 111.0), 19 (27.9%) patients had iron deficiency (13.8 ± 2.6; 88.8 ± 37.7) and none had iron overload. 34 
(50%) patients had low TSAT with normal or high serum ferritin.The history of medication intake included 
anti-hypertensive drugs in 64.7%, anti-DM in 22.1% and iron and calcium carbonate supplementation in 
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Table 1: The cause of CRF in the study patients under regular haemodialysis  
  
Etiology  No. of cases  (%)  
Diabetes Nephropathy  18  29.0  
Hypertension  13  21.0  
Glomerulonephritis  9  14.5  
Severe Malaria  8  13.0  
Renal stone  6  9.7  
Benign prostatic hyperplasia  3  4.8  
SLE  2  3.2  
Polycystic kidney  2  3.2  
Obstructive uropathy  1  1.6  
Total  62  100  
  
  
Table2: The complications among CRF patients under regular haemodialysis  
  
Etiology  No. of cases  (%)  
Hypertension  34  74.0  
Hypertension + Heart failure  6  13.0  
Deep vein thrombosis (DVT)  3  6.5  
Hypertension + DVT  2  4.3  
Peptic ulcer (stress)  1  2.2  
Total  46  100  
  
    
Table 3: Laboratory parameters of the study patients   
  
Parameters  Mean values  Range values  Normal 
Range  
Serum iron (ng/ml)  57.66 ± 27.9  14-183  50 -150  
Total iron binding capacity 
(ng/ml)  
294.3 ± 103.0  30-558  300 - 360  
Serum ferritin (ng/ml)  221.0 ± 170.1  20-764  50 -200  
TSAT (%)  22.8 ± 24.3  5-200  20 - 50  
  
Discussion:  
Our study showed that diabetes nephropathy was the commonest cause of ESRD occurring in 29% of the 
cases followed by hypertension in 13 (21%). Similarly diabetes nephropathy has been reported to be the 
commonest cause of ESRD in USA (5), Europe (6), Japan (4) and in Saudi Arabia (7). Also previous studies 
have reported that poor glycaemic control and inadequate control of hypertension are positively correlated 
with the rapid progression of diabetic nephropathy to ESRD (8, 9). Hypertension was also highly prevalent 
in our study, which was similar to that reported in the literature (10). However, control of hypertension 
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remains the most important strategy to halt the progression of renal failure (11). Glomerulonephritis 
accounted for 15% of cases of known aetiology in this study. This observation was accounted lower than 
previous reports in France (31%) (12), and in India (40%) (13). The reason for this difference could be related 
to the criteria used for the diagnosis as well as the sample size. The other possible explanation for these 
discrepancies are the difficulties in defining the exact cause of CRF in developing countries due to limitation 
of medical facilities, hence aetiology remains largely speculative in many cases. It is known that 
hypertension increases the risk of ESRD (14) and that good control of blood pressure will slow down the 
progression of CRF (15), prevent LVH and decrease cardiovascular mortality in CRF patients (16). Hence, 
Angiotensin converting enzyme (ACE) inhibitors and Angiotensin ІІ receptors blockers (ARB) are the 
preferred antihypertensive agents because of their benefits of retarding progression of renal disease and 
preventing cardiovascular events (17,18). A total of 62.3% of hypertensive patients of this study have received 
these drugs.   
The assessment of iron status is easy if both TSAT and serum ferritin are either low or normal in the study 
subjects. Serum ferritin has poor predictive value of iron status when there are infections and active 
inflammatory processes. Therefore, if these two values diverge, such as if the TSAT is low while the serum 
ferritin is high, iron status will still be interpreted as low and the raised serum ferritin is considered due to 
concomitant inflammatory process. Applying this in our study, 77.9% of the study subjects have low iron 
status, reflecting the necessity for thorough and meticulous care to assess these parameters in patients with 
CRF. Also serum ferritin should never be used alone to assess iron status. The difficulties in the 
interpretation of the above results demonstrate the need of applying more sensitive tests, such as percentage 
of circulating hypochromic red cells (HRC) and reticulocyte haemoglobin concentration (CHr) (19, 20).  
In conclusion, our study indicates that diabetes, hypertension and glomerulonephritis constitute the common 
causes of ESRD patients in Central Sudan and the iron status is low in the majority of these patients. Early 
diagnosis and management of these entities can play important role in slowing the progression of renal 
disease. The usage of new indices like HRC and CHr rather than TSAT and serum ferritin would likely 
make the diagnosis of iron status more accurate and may reduce the requirements and frequency of iron and 
EPO administration. Assessment of ferritin alone should be avoided particularly in patients with overt 
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